Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping the future of medicine and genetics.
CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...
On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...
Zacks Investment Research on MSN
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...
Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...
The influenza A virus (IAV) has been the cause of six major flu pandemics, responsible for 50 to 100 million deaths globally.
Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...
VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, Inc. for the use of select CRISPR-based ...
Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout ...
Intellia Therapeutics has temporarily stopped dosing and patient screening in two late-stage studies of its gene therapy after a participant developed serious liver injury, the company said on Monday, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback